A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Background Ketamine has rapid-acting antidepressant effects but is associated with psychotomimetic and other adverse effects. A 7-chlorokynurenic acid is a potent and specific glycine site N-methyl-d-aspartate receptor antagonist but crosses the blood-brain barrier inefficiently. Its prodrug, L-4-chlorokynurenine (4-Cl-KYN), exerts acute and sustained antidepressant-like effects in rodents and has no reported psychotomimetic effects in either rodents or healthy volunteers. This study examined whether 4-Cl-KYN has rapid antidepressant effects in individuals with treatment-resistant depression. Methods After a 2-week drug-free period, 19 participants with treatment-resistant depression were randomized to receive daily oral doses of 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days) or placebo for 14 days in a randomized, placebo-controlled, double-blind, crossover manner. The primary outcome measure was the Hamilton Depression Rating Scale score, assessed at several time points over a 2-week period; secondary outcome measures included additional rating scale scores. Pharmacokinetic measures of 7-chlorokynurenic acid and 4-Cl-KYN and pharmacodynamic assessments were obtained longitudinally and included 1H-magnetic resonance spectroscopy brain glutamate levels, resting-state functional magnetic resonance imaging, and plasma and cerebrospinal fluid measures of kynurenine metabolites and neurotrophic factors. Results Linear mixed models detected no treatment eff…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An additional small (n = 19) phase II crossover of AV-101 in individuals with TRD was also negative (p = 0.71, d = 0.22) [160].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [160]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 5×
“Subanesthetic doses of ketamine have demonstrated rapid antidepressant effects that manifest within a few hours in individuals with treatment-resistant unipolar MDD (Berman et al., 2000; Zarate et al., 2006; aan het Rot et al., 2010; Murrough et al., 2013) and bipolar depression (Diazgranados et al.”
BackgroundInfluentialAnticipatory and consummatory components of the experience of pleasure: A scale development study
Gard, D. E., Gard, M. G., Kring, A. M., & John, O. P. (2006) · Journal of Research in Personality · doi:10.1016/j.jrp.2005.11.001 · Cited by 1,015 · cited 2×
“The primary outcome measure was the 17-item HAM-D (Hamilton, 1960); secondary outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979), the Beck Depression Inventory (Beck and Beamesderfer, 1974), the Hamilton Anxiety Rating Scale (Hamilton, 1959), the Positive and…”
MethodDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“, 2013) and bipolar depression (Diazgranados et al., 2010; Zarate et al., 2012), a process proposed to occur via NMDAR inhibition (Trullas and Skolnick, 1990).”
BackgroundSelf-citationBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 2×
“The primary outcome measure was the 17-item HAM-D (Hamilton, 1960); secondary outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979), the Beck Depression Inventory (Beck and Beamesderfer, 1974), the Hamilton Anxiety Rating Scale (Hamilton, 1959), the Positive and…”
MethodZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Kemp, J. A., Foster, A. C., Leeson, P. D., Priestley, T., Tridgett, R., Iversen, L. L., & Woodruff, G. N. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6547 · Cited by 520
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Depression in the Primary Care Setting
Park, L. T., & Zarate, C. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1712493 · Cited by 458
Self-citationThe Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential
Leeson, P. D., & Iversen, L. L. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00050a001 · Cited by 315
Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Clinical features of treatment-resistant depression.
Kornstein, S. G., & Schneider, R. K. (2001) · PubMed · Cited by 258
Réus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Parsons, C. G., Danysz, W., Quack, G., Hartmann, S., Lorenz, B., Wollenburg, C., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37160-5 · Cited by 198
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 2×
“These findings contrast with previous results that found that 2 weeks of adjunctive treatment with high-dose DCS (1000 mg/d) had significant antidepressant effects in individuals with TRD (Heresco-Levy et al., 2013).”
BackgroundResultMitochondrial aspartate aminotransferase: a third kynurenate‐producing enzyme in the mammalian brain
Guidetti, P., Amori, L., Sapko, M. T., Okuno, E., & Schwarcz, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04556.x · Cited by 166
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citationMolecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133 · cited 1×
“Recent preclinical investigations, including comprehensive mechanistic cellular and molecular studies, support efforts to develop novel treatment approaches that robustly improve depressive symptoms within hours instead of weeks without ketamine’s most concerning adverse effects (Abdallah et al., 2018; Gould et al., 2…”
BackgroundSelf-citationZanos, P., Piantadosi, S. C., Wu, H., Pribut, H. J., Dell, M. J., Can, A., Snodgrass, H. R., Zarate, C. A., Schwarcz, R. M., & Gould, T. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225664 · Cited by 121
Self-citationActions of ?-cycloserine at the ? glycine receptor site in vivo
Emmett, M. R. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90161-4 · Cited by 108
Chen, M.-H., Cheng, C.-M., Gueorguieva, R., Lin, W.-C., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Krystal, J. H., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0480-y · Cited by 84
Miller, A. H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.140 · Cited by 83
Moaddel, R., Shardell, M., Khadeer, M., Lovett, J., Kadriu, B., Ravichandran, S., Morris, P. J., Yuan, P., Thomas, C. J., Gould, T. D., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4992-7 · Cited by 81
Self-citationFacilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid
Hokari, M., Wu, H.-Q., Schwarcz, R., & Smith, Q. R. (1996) · NeuroReport · doi:10.1097/00001756-199612200-00004 · Cited by 78
Wu, H., Salituro, F. G., & Schwarcz, R. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00829-1 · Cited by 47
Poleszak, E., Właź, P., Wróbel, A., Dybała, M., Sowa-Kućma, M., Fidecka, S., Pilc, A., & Nowak, G. (2007) · PubMed · Cited by 43
Wallace, M., White, A., Grako, K. A., Lane, R., Cato, A. (., & Snodgrass, H. R. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.05.004 · Cited by 33
Self-citationAnxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors.
Przegaliński, E., Tatarczynska, E., & Chojnacka-Wójcik, E. (1998) · PubMed · Cited by 22
Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents
Yaksh, T. L., Schwarcz, R. M., & Snodgrass, H. R. (2017) · Journal of Pain · doi:10.1016/j.jpain.2017.03.014 · Cited by 22
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration, 1997, Guidance document: dissolution testing of immediate release solid oral dosage forms (No. 97D-0331)
Cited by
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citationMuneer, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.507 · Cited by 159
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“However, a recent phase II, double-blind, 2-week, placebo-controlled, crossover study of 19 participants with TRD found that AV-101 monotherapy (either 1080 mg/day or 1440 mg/day) did not improve participants’ overall depressive symptoms (as assessed by HAM-D total score) [109].”
BackgroundSelf-citationAiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 137
Metadata
- Authors
- Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., Adeojo, L. W., Snodgrass, H. R., Smith, M. A., Henter, I. D., Machado-Vieira, R., Mannes, A. J., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- VistaGen Therapeutics (United States) (US)
- Augusta University (US)
- Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Science Center, Houston, TX
- Corresponding author
- Park, Lawrence T
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-31
- Volume
- 23
- Issue
- 7
- Pages
- 417-425
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7387765
- OpenAlex
- W3014355680
- Cited by
- 63
- References
- 47
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 11 · 2023: 6 · 2022: 14 · 2021: 13 · 2020: 9
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (ZIAMH002857, NCT02484456)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- treatment-resistant depression, 7-chlorokynurenic acid, prodrugs, antidepressant efficacy, psychotomimetic effects, kynurenine metabolites, brain glutamate, neurotrophic factors, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Animals, Antidepressive Agents, Brain, Brain Chemistry, Double-Blind Method, Female, Glycine, Humans, Kynurenine, Magnetic Resonance Imaging, Male, Middle Aged, Prodrugs, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Cross-Over Studies, Mice, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.